Shanghai Junshi Biosciences Co Ltd (688180) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Junshi Biosciences Co Ltd (688180) has a cash flow conversion efficiency ratio of -0.023x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-142.12 Million ≈ $-20.80 Million USD) by net assets (CN¥6.22 Billion ≈ $910.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanghai Junshi Biosciences Co Ltd (688180) net asset quality to measure how much of total assets are equity-financed.
Shanghai Junshi Biosciences Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Shanghai Junshi Biosciences Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688180 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Shanghai Junshi Biosciences Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Junshi Biosciences Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Galenica Sante AG
SW:GALE
|
0.129x |
|
Persimmon Plc
F:OHP
|
-0.038x |
|
Caihong Display Devices Co Ltd
SHG:600707
|
0.022x |
|
Jiangsu Guoxin Corp Ltd
SHE:002608
|
0.035x |
|
Guizhou Space Appliance Co Ltd
SHE:002025
|
-0.065x |
|
PBF Energy Inc
NYSE:PBF
|
0.005x |
|
Global Health Limited
NSE:MEDANTA
|
0.082x |
|
Dun & Bradstreet Holdings Inc.
NYSE:DNB
|
0.023x |
Annual Cash Flow Conversion Efficiency for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Shanghai Junshi Biosciences Co Ltd (688180) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.22 Billion ≈ $910.73 Million |
CN¥-478.14 Million ≈ $-69.97 Million |
-0.077x | +68.32% |
| 2024-12-31 | CN¥5.95 Billion ≈ $870.71 Million |
CN¥-1.44 Billion ≈ $-211.13 Million |
-0.242x | +11.46% |
| 2023-12-31 | CN¥7.32 Billion ≈ $1.07 Billion |
CN¥-2.00 Billion ≈ $-293.39 Million |
-0.274x | -51.10% |
| 2022-12-31 | CN¥9.79 Billion ≈ $1.43 Billion |
CN¥-1.78 Billion ≈ $-259.79 Million |
-0.181x | -135.29% |
| 2021-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
CN¥-641.90 Million ≈ $-93.93 Million |
-0.077x | +69.98% |
| 2020-12-31 | CN¥5.84 Billion ≈ $854.76 Million |
CN¥-1.50 Billion ≈ $-219.32 Million |
-0.257x | +35.40% |
| 2019-12-31 | CN¥2.99 Billion ≈ $437.31 Million |
CN¥-1.19 Billion ≈ $-173.70 Million |
-0.397x | -158.27% |
| 2018-12-31 | CN¥3.32 Billion ≈ $485.99 Million |
CN¥-510.76 Million ≈ $-74.74 Million |
-0.154x | +50.40% |
| 2017-12-31 | CN¥1.12 Billion ≈ $163.79 Million |
CN¥-347.08 Million ≈ $-50.79 Million |
-0.310x | -88.62% |
| 2016-12-31 | CN¥1.13 Billion ≈ $164.86 Million |
CN¥-185.21 Million ≈ $-27.10 Million |
-0.164x | -23.10% |
| 2015-12-31 | CN¥614.22 Million ≈ $89.88 Million |
CN¥-82.03 Million ≈ $-12.00 Million |
-0.134x | -9.00% |
| 2014-12-31 | CN¥319.87 Million ≈ $46.81 Million |
CN¥-39.19 Million ≈ $-5.73 Million |
-0.123x | -- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more